Your Daughter's Life, Their Bottom Line: Inside the NuvaRing Machine

An Essay

Preface

This essay owes its inspiration to Candace Owens and Episode 27 of her groundbreaking series A Shot in the Dark, where she exposed the horrifying truth about NuvaRing. In that devastating episode, she revealed how Erika Langhart died at 24 from pulmonary embolisms caused by this device, how Olympic athlete Megan Henry survived dozens of blood clots in her lungs, and how thousands of women have been killed or permanently damaged by a product that was never properly tested for temperature stability. Her investigation laid bare the entire corrupt system—from the 16-woman trial with suppressed data to the FDA committees stacked with pharmaceutical allies to the marketing campaigns that promised "freedom" while delivering death.

This is another part in my series of essays examining what the machine has done to women, following "The Birth Control Deception: What 60 Years of Lies Cost Women." But these essays aren't just about women—they're about all of us. What the machine has done to women, it has by extension done to men, to families, to the very fabric of human connection. The assault on female biology is an assault on humanity itself.

The oligarchy that rules us is fundamentally eugenicist. It’s documented in their own words, from the Rockefeller Foundation's funding of eugenics programs to Kissinger's NSSM 200 explicitly targeting population growth as a threat to resources. They are depopulationists who view human beings as "useless eaters" consuming limited resources. And above all else, they are interested in cheap labor—flooding the workforce with women not to liberate them but to halve the value of human work.

NuvaRing represents the perfect synthesis of these goals: population control through "convenient" contraception that harms and even kills the women who use it, corporate profits of $623 million annually built on suppressed safety data, and the transformation of healthy young women into either workers or patients or corpses—all outcomes serving the machine's purposes. The temperature bomb sitting in millions of women's bodies, untested above 77°F, releasing potentially lethal estrogen surges, is not a bug but a feature of a system that views female deaths as acceptable losses in the pursuit of profit and population reduction.

What Candace Owens revealed about NuvaRing—and what this essay expands upon—is that we are witnessing murder disguised as medicine, eugenics marketed as empowerment, and a holocaust of young women sacrificed to oligarchic interests. The tragedy is that these women trust a system that sees them as nothing more than units of production or statistics in a depopulation agenda.

Erika Langhart's death wasn't an accident. It was the predictable result of a machine operating exactly as designed.

1. The Numbers

$623 million. That's what NuvaRing earned Merck in 2012 alone, with 5.5 million prescriptions filled in 2010 at $15 to $80 per month. Set that number against another: 24. Erika Langhart's age when she died on Thanksgiving Day 2011, her boyfriend finding her writhing on the floor, struggling for air from the pulmonary embolism that would kill her within hours.

These two numbers define the NuvaRing machine—a system so perfectly calibrated that it transforms young women's bodies into revenue streams, their deaths into acceptable losses. Karen Langhart, Erika's mother, understood this with crystalline clarity when she wrote that pharmaceutical companies had "simply factored this in to their cost of doing business at the expense of young women." The machine runs on a simple equation: as long as the first number exceeds the settlements from the second, the product stays on the market.

The machine began its work in 2001 when NuvaRing received FDA approval. The press releases called it "birth control for the new millennium," with Dr. Larry Seidman declaring women would gain "freedom" and "spontaneity." The word "freedom" appeared constantly in early marketing—freedom from daily pills, freedom to be spontaneous, freedom from thinking about contraception. No one mentioned freedom from pulmonary embolisms.

By the time Merck acquired NuvaRing through its purchase of Schering-Plough in 2009, more than 100 cases had already been filed against the device. Merck didn't pause. Instead, they launched major new advertising campaigns featuring willowy dancers at ballet barres, their voices chirping "Oh!" as animated rings bounced across the screen. The upbeat music played while a voice mentioned, in the same lilting tone used for the product benefits, "serious risks include blood clots, stroke, and heart attacks."

The numbers accumulated on both sides of the ledger. Millions in prescriptions, thousands in adverse events. The FDA's own Kaiser Permanente study found women using NuvaRing long-term were 56 percent more likely to experience clots than those using older contraceptives. An independent Danish study of over one million women found NuvaRing users had 6.5 times the risk of blood clots compared to non-users—90 percent higher than older birth control pills.

Elite army athlete Megan Henry became a number in 2013 when dozens of blood clots filled her lungs. "If you weren't in the shape you are, you would be dead," her doctor told her. "Your career as an athlete is over." She was one of the lucky ones—she lived to become a plaintiff rather than a settlement.

The machine processes these numbers with perfect indifference. Each quarter, earnings calls report revenue. Each year, legal departments calculate settlement costs. The only math that matters is the subtraction: profit minus payouts equals shareholder value. Young women enter one side of the equation as customers and exit the other as liabilities, their lives compressed into actuarial calculations that determine whether a product stays profitable enough to remain on shelves.

2. The Patent Hustle

Organon Incorporated faced a problem in the 1990s: desogestrel, their third-generation progestin, was going off patent. Generic competitors would soon destroy their profit margins. But pharmaceutical companies have perfected a solution to expiring patents—take the same dangerous molecule, wrap it in a new delivery system, and restart the twenty-year monopoly clock.

The hustle works like this: you take a hormone that's already shown problems—third-generation progestins had been linked to double the blood clot risk of second-generation versions since the mid-1990s—and you don't fix the problem. You repackage it. Organon took desogestrel, combined it with ethinyl estradiol, embedded both in a flexible plastic ring made of ethylene vinylacetate copolymers, and called it innovation. The FDA approved NuvaRing in 2001, granting a new patent for essentially the same hormone that would soon be available as a generic pill for pennies.

This wasn't Organon's first dance with dangerous hormones. The Vanity Fair investigation revealed that the company marketed itself as committed to "thrombosis" research—an unusual commitment to advertise unless you're creating products that cause it. When Organon needed to submit safety data to the FDA, they ran a trial on exactly 16 women. During that trial, two women experienced massive spikes of estrogen in the first days. Two others had unexplained estrogen spikes midway through. These alarming data points vanished from the 30-page summary submitted to the FDA, buried instead in hundreds of pages of backup documentation where, as attorney Hunter Shkolnik explained, "the FDA is so understaffed it will never be noticed."

The acquisition chain reveals how toxic assets get laundered through corporate purchases. Organon developed the ring, then got acquired by Schering-Plough in 2007. When Schering-Plough marketed NuvaRing as delivering "the lowest dose of estrogen," they were comparing it to pills while ignoring that vaginal delivery creates different absorption patterns—patterns that were never properly studied. By 2009, when Merck purchased Schering-Plough for $41 billion, NuvaRing was earning $440 million annually. More than 100 lawsuits had already been filed, but Merck saw a "rising star" product that could fill their contraceptive gap.

Each acquisition added a layer of legal distance from the original fraud. Merck could claim they didn't conduct the original trials. Schering-Plough could claim they didn't design the product. Organon, absorbed into the corporate structure, effectively ceased to exist as a liable entity. The patent hustle isn't just about extending monopolies—it's about distributing culpability across so many corporate transformations that accountability dissolves.

The same game played out across the industry. Bayer's Yaz used a similar third-generation hormone and eventually paid billions in settlements. But the patents on these pills were expiring. The companies needed new delivery methods to maintain their monopolies. Patches, rings, implants—each iteration restarted the patent clock while carrying forward the same deadly risks. Johnson & Johnson's Ortho Evra patch saw sales drop 80 percent after the FDA mandated black-box warnings. Yet NuvaRing, using similar hormones, kept selling.

An Organon scientist, under oath in a deposition, stated he believed the company "had satisfied the American requirement." Not the scientific requirement. Not the safety requirement. The American requirement—a regulatory bar set so low that satisfying it becomes a bureaucratic exercise in documentary burial rather than a genuine assessment of whether a product will kill the young women who use it.

3. The Temperature Bomb

NuvaRing's package insert recommends storage between 68 and 77 degrees Fahrenheit. After leaving the pharmacy, it can be stored for up to four months at room temperature, with "excursions permitted" up to 86 degrees. But here's what the FDA never required and Merck never tested: what happens to this plastic ring when it sits in a delivery truck in Phoenix, in a purse during a Texas summer, or in a bathroom medicine cabinet where shower steam pushes temperatures past 90 degrees?

The Vanity Fair investigation exposed this oversight starkly: "To this day, no test has been made of NuvaRing after it leaves the factory." The polymer chemistry of ethylene vinylacetate copolymers changes with heat. The ring is designed to release precise doses—0.120 mg of etonogestrel and 0.015 mg of ethinyl estradiol daily. But polymers degrade. Heat accelerates chemical breakdown. Experts cited in court documents allege the ring could release "a possibly life-threatening surge of estrogen" when exposed to high temperatures. No one knows because no one tested it.

The original trial data hints at this instability. Among the 16 women Organon studied—a number so small it barely qualifies as a trial—four experienced severe hormone spikes. Two women had massive surges of estrogen in the first days of use. Two others showed unexplained estrogen spikes midway through their cycles. These weren't minor fluctuations. These were hormone surges significant enough that they should have triggered immediate investigation. Instead, these data points were deleted from the FDA submission without explanation, discovered only later through litigation discovery.

Consider the chemistry: NuvaRing contains 11.7 mg of etonogestrel and 2.7 mg of ethinyl estradiol embedded in plastic polymers. These hormones must diffuse through the polymer matrix at a controlled rate. Temperature affects diffusion rates exponentially—a basic principle of chemistry known since the 19th century. Yet the device women insert into the warmest part of their bodies, after unknown temperature exposures during transport and storage, has never been tested for thermal stability.

The Danish study that examined over one million women found NuvaRing users had a 90 percent greater risk of venous thromboembolism than users of birth control pills with earlier progestins. But even this massive study couldn't account for temperature variation. Were women in warmer climates at higher risk? Did summer months show more adverse events? The data doesn't exist because the question was never asked.

McKesson Corporation, the largest distributor of prescription drugs in North America, was named in Erika Langhart's lawsuit specifically because they would have to prove their cargo trucks and planes maintained temperature control. Hunter Shkolnik, the attorney representing the Langharts, understood that the distribution chain itself might be liable if temperature excursions caused hormone surges that killed women.

The implications extend beyond individual tragedies. Every NuvaRing sitting in every pharmacy, every purse, every medicine cabinet is a potential temperature bomb. The molecule etonogestrel—the active metabolite of desogestrel—is known to increase clotting risk. Ethinyl estradiol, the synthetic estrogen, also increases thrombosis risk. When these molecules release in unexpected surges due to polymer degradation from heat exposure, the risk doesn't just add—it multiplies.

Women become unwitting experimenters in polymer chemistry, their bodies the laboratories where untested temperature variations play out in blood vessels and lung tissue. The machine counts successful deliveries and filled prescriptions, not the temperature logs that don't exist or the stability studies that were never performed.

4. The Script

Thomas Hadley, Schering-Plough's marketing supervisor, sent an email in October 2009 that revealed the machine's operating manual: "Do we have anything for the reps to use to help direct the conversation away from DVT? Didn't we create a letter for them to use reactively?" DVT—deep vein thrombosis—the blood clots that travel to lungs and kill young women. Hadley wanted scripts to deflect discussion from the very side effect killing NuvaRing users.

The court documents exposed an entire campaign designed to "nullify concerns about blood clot risks with NuvaRing." A "Field Flash" communication from July 20, 2005, provided sales representatives with exact language for responding to doctors' cardiovascular concerns. The script instructed reps to emphasize that risks were "relatively small" and that NuvaRing produced "a low and steady daily dose of 15 mcg EE and 120 mcg etonogestrel." It ended with a closing question designed to secure the sale: "Based on this information are you still confident and comfortable in prescribing NuvaRing to your patients seeking hormonal contraception?"

The scripts weren't limited to sales reps. They permeated medical practice itself. The Vanity Fair investigation sent two college students undercover to New York clinics. Both young women specifically mentioned family histories of heart disease and diabetes—clear risk factors for blood clots. At a Planned Parenthood clinic in Brooklyn, when one student mentioned Googling NuvaRing lawsuits about blood clots, the nurse practitioner responded: "NuvaRing is safe for healthy young women... You seem a good candidate. Would you like to try it?"

At a Manhattan university clinic, another student with family health risks received the same casual dismissal of concerns. The doctor "simply opened her desk drawer and gave her a sample." No warnings about blood clots. No discussion of family history implications. No mention that third-generation progestins carry double the clotting risk. The script had replaced medical judgment.

Dr. Larry Seidman's initial PR statement reveals how scripts shaped NuvaRing's entire narrative: "Women are always searching for more convenient contraceptive options... NuvaRing is effective, yet is administered only once a month, and gives women more freedom." The word "searching" implies women demanded this product. "Convenient" and "freedom" become the approved vocabulary, while "thrombosis" and "pulmonary embolism" remain unscripted, unspoken.

Marketing materials reinforced these scripts visually. The commercial shows ballet dancers warming up to bouncing plastic rings and cheerful exclamations of "Oh!" The FDA-mandated risk warnings flow past in the same upbeat tone used for product benefits: "Serious risks include blood clots, stroke, and heart attacks... Some studies suggest that the progestin in NuvaRing may increase the risk for blood clots." The script makes death sound like a minor inconvenience between dance classes.

Bill Drummy, CEO of Heartbeat, the digital agency that advertised NuvaRing, was blunt about their target: "We weren't trying to sell to nuns." They pushed hard on Facebook and social media, crafting scripts for young women to share with friends. "Not Your Everyday Birth Control" became the tagline, with the ring displayed as a halo following women throughout their days.

Behind these public scripts lay private ones. During litigation, doctors testified that they would never prescribe third- or fourth-generation contraceptives and wouldn't allow their own daughters to use them. Yet these same doctors worked in systems where the scripts—from pharmaceutical training, from clinic protocols, from insurance formularies—overrode personal judgment. The machine runs on scripts that transform medical encounters into sales transactions, informed consent into rehearsed persuasion, and clinical caution into competitive disadvantage.

5. The Freedom Trap: Trading Fertility for Corporate Servitude

The word "freedom" appears in every iteration of birth control marketing from 1960 to today. Freedom from pregnancy. Freedom to pursue careers. Freedom from biological constraints. Freedom to be spontaneous. Dr. Larry Seidman's press release for NuvaRing in 2001 used the word three times in two paragraphs. But this freedom, as millions of women are discovering too late, was the cheese in a particularly cruel trap.

The machine convinced women that their fertility—their singular power to create life—was a burden to be suppressed, delayed, or eliminated. The pill would free them from the "slavery" of motherhood. The ring would liberate them from thinking about contraception. Abortion would ensure no "mistake" could derail their careers. Each innovation promised more freedom while stealing more of women's essential power.

The reality beneath the marketing reveals itself in the statistics. Women's happiness has declined steadily since the 1970s despite achieving every feminist goal. Antidepressant use among women has doubled in the last decade. One in four middle-aged women takes psychiatric medication. The most liberated generation of women in history is also the most medicated, the most anxious, and the most alone.

Consider what this "freedom" actually delivered. Women traded the power to create life for the privilege of creating PowerPoints. They exchanged the respect accorded to mothers for the chance to compete with men in workplaces that require them to act like men to succeed. They gave up families that would love them unconditionally for corporations that will discard them the moment their productivity declines.

The fertility window is narrow—roughly 15 years of peak reproductive potential. The machine convinced women to spend those years on birth control, building careers that can be destroyed by a single recession or a younger replacement. By the time women realize they want children, their fertility has often declined past the point of recovery. IVF clinics—charging $20,000 per cycle with a 20% success rate for women over 40—represent the machine's final extraction of value from women it has already stripped of their natural power.

The loneliness epidemic among professional women isn't coincidental. The machine that promised them "having it all" delivered empty apartments, frozen eggs that may never become children, and dating apps full of men who learned that commitment is foolish in a culture that celebrates female infidelity as empowerment. These women scroll through Instagram watching their few married friends post family photos while they schedule another wine night with other single professionals to complain about the lack of "good men."

Even women who manage both career and family discover the freedom was a lie. They're "free" to work full-time while managing households, free to pay strangers to raise their children, free to collapse from exhaustion while being told they should be grateful for the opportunity. The second shift became the third shift became the permanent shift. Liberation looks remarkably like exploitation with better branding.

The cruelest aspect is how the machine severs women from their own bodies. Birth control doesn't just prevent pregnancy—it fundamentally alters women's hormonal reality, their attraction patterns, their emotional regulation. Women on the pill are attracted to different types of men than when they're naturally cycling. They experience muted emotions, decreased libido, increased depression. The machine literally changes who women are at a biochemical level, then tells them this artificial state is their authentic self.

The connection between hormonal contraception and depression is particularly damning. Multiple studies show women on birth control have significantly higher rates of depression and suicide. The Danish study of over one million women found those on hormonal contraception had a 70% higher rate of depression. Teenage girls on birth control had a 130% higher rate. The machine's "freedom" requires women to chemically lobotomize themselves.

When women try to voice their regret—when they admit they want families more than careers, when they confess that casual sex left them feeling empty, when they acknowledge that fertility is power not burden—they're attacked by other women still invested in the lie. The machine has created an enforcement mechanism where women police each other's acceptance of biological reality. Admitting you want children becomes betrayal of the sisterhood.

The women who avoided the trap—who married young, had children, and built families instead of careers—are dismissed as "tradwives" or victims of internalized misogyny. Yet studies consistently show these women report higher life satisfaction, better mental health, and stronger social connections. They have what liberated women are desperately seeking on dating apps and in therapy sessions: purpose, connection, and love.

The machine's ultimate victory is convincing women that their greatest power—the ability to create and nurture life—is their greatest weakness. It transformed fertility from a source of reverence and respect into a medical condition to be treated with synthetic hormones. It converted the profound experience of motherhood into an impediment to real accomplishment, which could only be measured in salary figures and job titles.

But bodies keep score. The epidemic of autoimmune disorders among professional women, the proliferation of "unexplained infertility," the rise in pregnancy complications among older mothers—these are the physical manifestations of a culture at war with female biology. The machine can suppress fertility temporarily, but it cannot eliminate the consequences of denying biological reality.

6. The Kangaroo Court

Karen Langhart called it perfectly when she described the FDA's Drug Safety and Risk Management Advisory Committee as "a kangaroo court where reality seemed scripted by the drug companies." She had rushed to attend the December 2011 hearing days after her daughter Erika's death, expecting NuvaRing would be discussed alongside Yaz and Yasmin. It wasn't even on the agenda.

The committee's construction reveals systematic capture. Chairman Vincent Lo's resume runs for pages—International Society for Pharmacoepidemiiology member, American Association for the Study of Liver Disease, American College of Epidemiology, countless boards and foundations. Each membership, each grant, each fellowship creates another financial thread connecting regulators to the industry they supposedly regulate. The FDA's own documents show these committee members receiving grants from pharmaceutical companies, sitting on boards funded by drug manufacturers, belonging to societies sponsored by the very companies whose products they evaluate.

The FDA's financial entanglements run deeper than individual committee members. The agency awarded over $500 million to True North Communications between 2017 and 2023, with another $287 million allocated through 2025. True North's website describes their specialty: "strategic government and media relations counsel... public relations, lobbying, advocacy and managing crises." The FDA pays hundreds of millions to a PR firm for crisis management while young women die from inadequately tested drugs.

Two days before the December 2011 panel convened, something extraordinary happened. Dr. Sidney Wolfe, head of the Health Research Group at Public Citizen, was stripped of his voting rights. Wolfe had warned the FDA for years about third-generation progestins' dangers. His disqualification? "Intellectual conflict of interest." He knew too much, cared too strongly about safety. Meanwhile, committee members with financial ties to pharmaceutical companies kept their voting privileges.

The hearing's agenda excluded crucial evidence. Dr. David Kessler, former FDA commissioner, had prepared a scathing report on Bayer's Yaz and Yasmin for plaintiffs' lawyers. The report contained evidence directly relevant to all third-generation progestins, including NuvaRing's. The committee refused to consider it. Karen and Rick Langhart requested time to tell Erika's story. "The deadline has passed," a staffer told them. Karen snapped back: "My daughter happened to be dying in the I.C.U. I couldn't register." Only Senator John McCain's office intervention got them a hearing.

The FDA had just received its own commissioned Kaiser Permanente study showing NuvaRing users were 56 percent more likely to experience clots than users of older contraceptives. Dr. Stephen Sidney supervised this research—clear, independent evidence of elevated risk. Yet in the packed auditorium of drug company executives, lawyers, and scientists, Merck presented a company-funded study claiming "no increased risk." Merck's study won first place at the conference. The German doctor presenting wasn't even the paper's author, but he concluded with confidence: "Therefore, a twofold risk for NuvaRing can be excluded."

The revolving door spun most visibly with Dr. Susan Allen. She oversaw birth control products at the FDA, then retired mid-crisis to immediately become a consultant—with NuvaRing as her first client. Her FDA salary: approximately $150,000 annually. Her consulting fees: far more, according to attorneys who deposed her. She now serves as Merck's expert witness in lawsuits brought by women harmed by the product she once regulated.

Hunter Shkolnik described deposing Allen as "one of the most disgusting displays of everything that is wrong with our regulatory system." He wanted to ask her directly: "That doesn't stink to you?" But the kangaroo court operates beyond shame. Its performers read their lines, collect their payments, and validate predetermined outcomes while women die from a device that should never have been approved.

7. The Bodies

Erika Langhart was 24, beautiful, bound for law school. On Thanksgiving Day 2011, her boyfriend arrived at her apartment at 6:30 PM to find her writhing on the floor, struggling for air. The pulmonary embolism that had traveled from her leg to her lungs was killing her. Three hours later, despite desperate medical intervention, she was dead. Her mother Karen, a physician herself, spent three days in the ICU watching her daughter die. Every nurse, every doctor had stories about birth control and pulmonary embolisms. "Each and every one of them had personal and professional stories to tell," Karen said. They'd seen this before. They would see it again.

Megan Henry was luckier—if you can call dozens of blood clots in your lungs lucky. An elite army athlete, she'd been training intensely when she couldn't catch her breath during drills. She thought it was altitude adjustment at first. Then came the stabbing chest pain. She'd been on NuvaRing for three years. The CT scan revealed the full horror: her lungs were peppered with clots. "If you weren't in the shape you are, you would be dead," her doctor told her. She spent a week hospitalized on blood thinners. Her athletic career ended at 29. The machine had processed another body.

The bodies accumulate in court documents—thousands of adverse event reports, each representing a woman whose blood betrayed her. The mechanism is always similar: synthetic hormones increase clotting factors, blood thickens, a clot forms—usually in the deep veins of the legs. Then it breaks free, traveling through the venous system to the lungs where it lodges in the pulmonary arteries. If the clot is large enough or if multiple clots arrive, oxygen can't reach the blood. The woman suffocates from the inside.

Young women's bodies are particularly profitable for the machine. They're healthy, so doctors dismiss risk factors. They're busy, so monthly contraception appeals. They're trusting, so they believe safety assurances. The Danish study of over one million women found those using NuvaRing were 6.5 times more likely to suffer venous thromboembolism than non-users. But statistics don't capture the specific cruelty of these deaths—young women in their prime, athletes like Megan, future lawyers like Erika, dying from a device marketed with dancing ballerinas.

The genetic lottery makes some bodies more vulnerable. Factor V Leiden, a clotting disorder affecting 5 percent of Caucasians, increases thrombosis risk 35-fold when combined with hormonal contraception. No one screens for it before prescribing NuvaRing. The machine doesn't differentiate between bodies—it processes them all equally until they either generate revenue or become lawsuits.

Some bodies provide warnings the machine ignores. During Organon's 16-woman trial, four participants experienced massive hormone spikes that could trigger clotting cascades. These bodies were trying to tell researchers something was wrong. Their data was deleted from the FDA submission. The machine doesn't want bodies that complain during trials—it wants bodies that comply during sales.

Barbara Henry, Megan's mother, emailed friends: "Make sure to tell this story. It may save somebody's life." But stories of bodies don't travel as efficiently as marketing scripts. For every family desperately sharing warnings, the machine produces thousands of new prescriptions. Ballet dancers keep leaping across screens while young women's lungs fill with clots.

The machine processes bodies with pristine efficiency: insert ring, collect payment, document adverse event, calculate settlement, recruit replacement customer. The only inefficiency is when bodies like Megan's survive to testify, when families like the Langharts refuse silence, when the accumulated weight of dead young women briefly disrupts the mechanism before it resumes its perfect operation.

8. The Machine Perfected

The NuvaRing machine operates through interlocking systems, each component precisely calibrated to maximize profit while diffusing responsibility. At the molecular level, untested polymers degrade in heat, releasing hormone surges no one measured. At the corporate level, patents expire and get repackaged, dangerous molecules wrapped in new delivery systems. At the regulatory level, committees stacked with grant recipients validate predetermined approvals. At the clinical level, doctors recite scripts that deflect from blood clots. At the marketing level, dancers promise freedom while risk warnings float past in sing-song tones. Every level meshes perfectly to convert women's bodies into revenue.

The machine's genius lies in making each component appear independent. The FDA seems separate from pharmaceutical companies, yet pays $500 million to PR firms for "crisis management." Medical journals appear objective, yet publish Merck-funded studies that win conference prizes while independent Danish research documenting 6.5 times higher clotting risk gets buried. Doctors seem autonomous, yet operate within systems where insurance formularies, pharmaceutical training, and clinic protocols override clinical judgment.

Consider the precision: 5.5 million prescriptions yearly become unwitting participants in an ongoing experiment. Each woman becomes a data point in a trial that was never properly conducted. The original 16-woman study was a gesture toward compliance, not science. The real trial runs continuously across millions of bodies, generating data the machine chooses to ignore. Women report depression, anxiety, decreased libido—subjective symptoms dismissed as "unrelated." They develop clots—objective events buried in adverse event databases. They die—statistical outliers factored into profit projections.

The machine perfects itself through evolution. When Ortho Evra patches caused outcry, sales dropped 80 percent after FDA black-box warnings. The machine learned: maintain steady background noise about all contraceptive risks so specific dangers get lost in generalized warnings. When Yaz settlements reached billions, the machine adapted: acquire companies to distribute liability, create legal distance between patent holders and victims. When critics like Dr. Sidney Wolfe raise alarms, the machine responds: strip voting rights for "intellectual conflicts" while maintaining members with financial conflicts.

The genetic dimension reveals the machine's most cynical calculation. Factor V Leiden affects 5 percent of Caucasians, increasing clot risk 35-fold with hormonal contraception. Protein S or Protein C deficiencies create similar vulnerabilities. The machine could screen for these conditions—the tests exist, the risk factors are known. But screening would reduce the customer base. Better to let genetic roulette play out across millions of bodies, settling with the unlucky while maintaining market share.

The neurochemical effects expose another perfected cruelty. Synthetic hormones cross the blood-brain barrier, altering neurotransmitter systems. Progesterone metabolites modulate GABA receptors. Synthetic progestins increase monoamine oxidase, degrading serotonin. Women report mood changes, cognitive effects, sexual dysfunction. The machine classifies these as "subjective" symptoms, impossible to quantify, therefore dismissible. The brain changes are real—imaging studies show structural alterations in contraceptive users—but the machine profits from pretending consciousness doesn't count.

Temperature instability becomes a feature, not a bug. Rings stored improperly might release hormone surges, but proving causation requires temperature logs that don't exist, stability studies never conducted. The machine operates in the space between plausible deniability and proven harm, extracting profit from uncertainty while women absorb risk.

The machine has achieved perpetual motion. Money flows up through acquisition chains and patent extensions. Bodies flow down through marketing funnels and prescription pipelines. Death gets processed as data, settlements as operating costs, grief as externality. The machine runs so smoothly that disrupting it seems impossible—it has captured its regulators, scripted its practitioners, and converted its victims into revenue streams before they become liabilities.

9. The Bottom Line

Karen Langhart understood everything when she wrote that pharmaceutical companies had "simply factored this in to their cost of doing business." The phrase appears matter-of-fact, but it contains the entire horror: these companies calculate how many women will die, multiply by expected settlement costs, and subtract from projected revenue. If the number remains positive, the product stays on market.

The math is straightforward. NuvaRing earned Merck $623 million in 2012. With 5.5 million prescriptions filled in 2010 at $15-80 monthly, annual revenue reaches into billions over the patent life. Against this: settlements. Erika Langhart's death, Megan Henry's destroyed athletic career, thousands of other women with clots, strokes, embolisms. Individual settlements rarely exceed a few million. The arithmetic favors keeping NuvaRing on shelves.

Attorney Hunter Shkolnik has seen these calculations throughout his career fighting pharmaceutical companies. After Merck's Vioxx killed thousands through heart attacks, the company paid $4.85 billion to settle 27,000 lawsuits. Vioxx had earned $2.5 billion in 2003 alone. The math worked—profits exceeded payments. Ken Frazier, who orchestrated Merck's refusal to settle early, became chairman. The lesson: fight every case, delay every payment, maximize revenue until forced to stop.

"It is criminal what they do," one plaintiff's attorney said. "And yet none of the executives are in jail. In America, corporations are thought of as people. And the only way you can harm them is to get money out of them. But the billions they allot for these settlements rarely harm them." The machine has priced in death as a cost center, as predictable as manufacturing or marketing.

The bottom line extends beyond corporate accounting to societal calculations. The FDA receives over $500 million for PR firms to manage crises rather than prevent them. Medical schools receive grants from pharmaceutical companies that shape curriculum. Insurance companies privilege formularies that favor profitable drugs over safer alternatives. The entire healthcare system has been calibrated to accept a certain number of young women's deaths as the price of contraceptive innovation.

Dr. Sidney Wolfe, stripped of his voting rights for knowing too much about third-generation progestins, represents the voices excluded from these calculations. Independent researchers like Dr. Øjvind Lidegaard, whose Danish study revealed NuvaRing's true risks, operate outside the machine's funding streams. Their data threatens the bottom line, so the machine marginalizes their findings while promoting industry-funded studies claiming safety.

The most honest statement came from an Organon scientist who said they had "satisfied the American requirement." Not the ethical requirement or the scientific requirement, but the American requirement—a standard so degraded that meeting it means merely avoiding criminal prosecution while maximizing profit. The American requirement allows 16-woman trials with deleted data. It permits untested temperature stability. It enables marketing freedom while delivering death.

Every prescription written represents this calculation. A young woman walks into a clinic seeking contraception. The machine has already determined her statistical value—likely revenue minus potential settlement. If she has Factor V Leiden, she's 35 times more likely to develop clots, but no one tests because screening would reduce profits. If she stores her ring in a hot climate, it might release lethal hormone surges, but no one warns because temperature testing would reveal instability. If she develops depression from neurochemical disruption, it's classified as subjective and dismissed.

Karen Langhart channels her grief into advocacy, knowing the machine has already factored in her activism. The calculation includes everything: the probability of media attention, the cost of legal defense, the likelihood of regulatory action, the impact on stock price. Dead daughters become variables in equations that always solve for profit. The machine's ultimate efficiency is that it has made this calculation visible—everyone can see it, know it, name it—and yet it continues operating, converting young women's lives into the only bottom line that matters: shareholder value.

References

Primary Sources

• FDA NuvaRing Product Insert - Official prescribing information and warnings

Fda Insert Nuvaring

748KB ∙ PDF file

Download

Download

• Vanity Fair Investigation (December 2013) - "Danger in the Ring" by Marie Brenner

Is The Contraceptive Nuvaring Killing Thousands The Full Investigation Vanity Fair

4.82MB ∙ PDF file

Download

Download

• A Shot in the Dark Episode 27 Transcript - Podcast/video transcript discussing marketing and FDA corruption

• Long-Term Physical and Psychological Effects of Extended NuvaRing Use - Research framework document

Long Term Physical And Psychological Effects Of Extended Nuvaring Use Comprehensive Research Framew

208KB ∙ PDF file

Download

Download

Key Statistics & Studies

• Danish Study - Over 1 million women; found 6.5x higher VTE risk for NuvaRing users

• Kaiser Permanente Study - FDA-commissioned; found 56% increased clot risk

• British Medical Journal (2012) - 90% greater VTE risk for vaginal rings vs. earlier pills

• Organon Trial Data - Original 16-woman trial with suppressed estrogen spike data

Legal Documents

• Court filings against Merck - Including internal emails from Thomas Hadley about deflecting DVT concerns

• Langhart v. Merck - Erika Langhart's case documents

• Expert testimony - Depositions from Dr. Susan Allen and other FDA officials

Corporate/Regulatory Documents

• USA Spending.gov records - FDA payments to True North Communications ($500M+)

• FDA Drug Safety Committee rosters - Committee member affiliations and conflicts

• Merck financial reports - $623 million NuvaRing revenue (2012)

Individual Cases

• Erika Langhart - 24-year-old law student, died Thanksgiving 2011

• Megan Henry - Elite army athlete, survived dozens of lung clots

• Multiple plaintiff testimonies - From over 1,000 lawsuits filed

I appreciate you being here.

If you've found the content interesting, useful and maybe even helpful, please consider supporting it through a small paid subscription. While 99% of everything here is free, your paid subscription is important as it helps in covering some of the operational costs and supports the continuation of this independent research and journalism work. It also helps keep it free for those that cannot afford to pay.

Please make full use of the Free Libraries.

Unbekoming Interview Library: Great interviews across a spectrum of important topics.

Unbekoming Book Summary Library: Concise summaries of important books.

Stories

I'm always in search of good stories, people with valuable expertise and helpful books. Please don't hesitate to get in touch at unbekoming@outlook.com

Baseline Human Health

Watch and share this profound 21-minute video to understand and appreciate what health looks like without vaccination.